// <auto-generated/>
// Contents of: hl7.fhir.r4.core version: 4.0.1
// Minimum TypeScript Version: 3.7
// FHIR ValueSet: http://hl7.org/fhir/ValueSet/research-study-phase|4.0.1
import { Coding } from '../fhir/Coding.js';
/**
 * Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.
 */
export const ResearchStudyPhaseCodings = {
    /**
     * early-phase-1: Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.
     */
    EarlyPhase1: new Coding({
        display: "Early Phase 1",
        code: "early-phase-1",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
    /**
     * n-a: Trials without phases (for example, studies of devices or behavioral interventions).
     */
    NA: new Coding({
        display: "N/A",
        code: "n-a",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
    /**
     * phase-1: Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
     */
    Phase1: new Coding({
        display: "Phase 1",
        code: "phase-1",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
    /**
     * phase-1-phase-2: Trials that are a combination of phases 1 and 2.
     */
    Phase1Phase2: new Coding({
        display: "Phase 1/Phase 2",
        code: "phase-1-phase-2",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
    /**
     * phase-2: Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
     */
    Phase2: new Coding({
        display: "Phase 2",
        code: "phase-2",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
    /**
     * phase-2-phase-3: Trials that are a combination of phases 2 and 3.
     */
    Phase2Phase3: new Coding({
        display: "Phase 2/Phase 3",
        code: "phase-2-phase-3",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
    /**
     * phase-3: Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
     */
    Phase3: new Coding({
        display: "Phase 3",
        code: "phase-3",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
    /**
     * phase-4: Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
     */
    Phase4: new Coding({
        display: "Phase 4",
        code: "phase-4",
        system: "http://terminology.hl7.org/CodeSystem/research-study-phase",
    }),
};
//# sourceMappingURL=data:application/json;base64,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